Last reviewed 2026-04-20 · How we verify

Veklury

Veklury, marketed by ANRS, Emerging Infectious Diseases, is a nucleoside analog prodrug approved for treating diseases caused by SARS-CoV-2. Its key strength lies in its mechanism of inhibiting viral RNA-dependent RNA polymerase, effectively blocking viral replication. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Approved indications

• Disease caused by Severe acute respiratory syndrome coronavirus 2

Pipeline indications

Common side effects

• Nausea
• ALT increased
• AST increased

Key clinical trials

• A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised (PHASE3)
• Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals (PHASE2)
• OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial (PHASE2)
• An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID. (PHASE4)
• OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients (PHASE2)
• AGILE (Early Phase Platform Trial for COVID-19) (PHASE1, PHASE2)
• Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients (PHASE2)
• COVID-19 International Drug Pregnancy Registry

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Veklury CI brief — competitive landscape report
• Veklury updates RSS · CI watch RSS
• ANRS, Emerging Infectious Diseases portfolio CI